118 related articles for article (PubMed ID: 25812606)
1. Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells.
Baldan F; Mio C; Lavarone E; Di Loreto C; Puglisi F; Damante G; Puppin C
Oncol Rep; 2015 May; 33(5):2199-206. PubMed ID: 25812606
[TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
[TBL] [Abstract][Full Text] [Related]
3. The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines.
Lavarone E; Puppin C; Passon N; Filetti S; Russo D; Damante G
Mol Cell Endocrinol; 2013 Jan; 365(1):1-10. PubMed ID: 22982218
[TBL] [Abstract][Full Text] [Related]
4. Synergistic suppressive effect of PARP-1 inhibitor PJ34 and HDAC inhibitor SAHA on proliferation of liver cancer cells.
Liang BY; Xiong M; Ji GB; Zhang EL; Zhang ZY; Dong KS; Chen XP; Huang ZY
J Huazhong Univ Sci Technolog Med Sci; 2015 Aug; 35(4):535-540. PubMed ID: 26223923
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic Modifications with DZNep, NaBu and SAHA in Luminal and Mesenchymal-like Breast Cancer Subtype Cells.
Dagdemir A; Judes G; Lebert A; Echegut M; Karsli-Ceppioglu S; Rifaï K; Daures M; Ngollo M; Dubois L; Penault-Llorca F; Bignon YJ; Bernard-Gallon D
Cancer Genomics Proteomics; 2016; 13(4):291-303. PubMed ID: 27365379
[TBL] [Abstract][Full Text] [Related]
6. Histone post-translational modifications induced by histone deacetylase inhibition in transcriptional control units of NIS gene.
Baldan F; Lavarone E; Di Loreto C; Filetti S; Russo D; Damante G; Puppin C
Mol Biol Rep; 2014 Aug; 41(8):5257-65. PubMed ID: 24844212
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer.
Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997
[TBL] [Abstract][Full Text] [Related]
8. Histone acetylation of glucose-induced thioredoxin-interacting protein gene expression in pancreatic islets.
Bompada P; Atac D; Luan C; Andersson R; Omella JD; Laakso EO; Wright J; Groop L; De Marinis Y
Int J Biochem Cell Biol; 2016 Dec; 81(Pt A):82-91. PubMed ID: 27989964
[TBL] [Abstract][Full Text] [Related]
9. Histone lysine trimethylation or acetylation can be modulated by phytoestrogen, estrogen or anti-HDAC in breast cancer cell lines.
Dagdemir A; Durif J; Ngollo M; Bignon YJ; Bernard-Gallon D
Epigenomics; 2013 Feb; 5(1):51-63. PubMed ID: 23414320
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial effects of PARP inhibitor PJ34 and histone deacetylase inhibitor vorinostat on leukemia cell lines.
Jasek E; Gajda M; Lis GJ; Jasińska M; Litwin JA
Anticancer Res; 2014 Apr; 34(4):1849-56. PubMed ID: 24692719
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors.
Lapierre M; Linares A; Dalvai M; Duraffourd C; Bonnet S; Boulahtouf A; Rodriguez C; Jalaguier S; Assou S; Orsetti B; Balaguer P; Maudelonde T; Blache P; Bystricky K; Boulle N; Cavaillès V
Oncotarget; 2016 Apr; 7(15):19693-708. PubMed ID: 26930713
[TBL] [Abstract][Full Text] [Related]
12. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
13. Modulation of radiation response by histone deacetylase inhibition.
Chinnaiyan P; Vallabhaneni G; Armstrong E; Huang SM; Harari PM
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):223-9. PubMed ID: 15850925
[TBL] [Abstract][Full Text] [Related]
14. Hypoxic silencing of tumor suppressor RUNX3 by histone modification in gastric cancer cells.
Lee SH; Kim J; Kim WH; Lee YM
Oncogene; 2009 Jan; 28(2):184-94. PubMed ID: 18850007
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of lymphangiogenic factor VEGF-C expression and production by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in breast cancer cells.
Cheng HT; Hung WC
Oncol Rep; 2013 Mar; 29(3):1238-44. PubMed ID: 23242251
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia increases genome-wide bivalent epigenetic marking by specific gain of H3K27me3.
Prickaerts P; Adriaens ME; Beucken TVD; Koch E; Dubois L; Dahlmans VEH; Gits C; Evelo CTA; Chan-Seng-Yue M; Wouters BG; Voncken JW
Epigenetics Chromatin; 2016; 9():46. PubMed ID: 27800026
[TBL] [Abstract][Full Text] [Related]
17. Comparative effects of histone deacetylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells.
Knutson AK; Welsh J; Taylor T; Roy S; Wang WL; Tenniswood M
Oncol Rep; 2012 Mar; 27(3):849-53. PubMed ID: 22159450
[TBL] [Abstract][Full Text] [Related]
18. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic alteration of the NF-κB-inducing kinase (NIK) gene is involved in enhanced NIK expression in basal-like breast cancer.
Yamamoto M; Ito T; Shimizu T; Ishida T; Semba K; Watanabe S; Yamaguchi N; Inoue J
Cancer Sci; 2010 Nov; 101(11):2391-7. PubMed ID: 20735436
[TBL] [Abstract][Full Text] [Related]
20. Long-term genistein treatment of MCF-7 cells decreases acetylated histone 3 expression and alters growth responses to mitogens and histone deacetylase inhibitors.
Jawaid K; Crane SR; Nowers JL; Lacey M; Whitehead SA
J Steroid Biochem Mol Biol; 2010 Jun; 120(4-5):164-71. PubMed ID: 20399854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
